Ivan Urits1, Mark R Jones2, Kyle Gress3, Karina Charipova3, Jacob Fiocchi4, Alan D Kaye5, Omar Viswanath6,7,8. 1. Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. iurits@bidmc.harvard.edu. 2. Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. 3. Georgetown University School of Medicine, Washington, DC, USA. 4. Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, AZ, USA. 5. Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 6. Valley Anesthesiology and Pain Consultants, Phoenix, AZ, USA. 7. University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA. 8. Creighton University School of Medicine, Omaha, NE, USA.
Abstract
PURPOSE OF REVIEW: The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist. RECENT FINDINGS: Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
PURPOSE OF REVIEW: The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist. RECENT FINDINGS: Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
Authors: Nazir Noor; Alexis Angelette; Abby Lawson; Anjana Patel; Ivan Urits; Omar Viswanath; Cyrus Yazdi; Alan D Kaye Journal: Health Psychol Res Date: 2022-06-28
Authors: Amnon A Berger; Ariel Winnick; Austin H Carroll; Alexandra Welschmeyer; Nathan Li; Marc Colon; Antonella Paladini; Giovanni F Ramírez; Jamal Hasoon; Elyse M Cornett; Jaehong Song; Giustino Varrassi; Adam M Kaye; Alan D Kaye; Latha Ganti Journal: Health Psychol Res Date: 2022-10-12
Authors: Jing Zhu; Mahdieh Dagina Pedersen; Laraib Sabbah Ahmed; Bahareh Abdolalizadeh; Anne-Sofie Grell; Jais Oliver Berg; Peter Waaben Thulstrup; Henrik Franzyk; Lars Edvinsson; Anette Sams; Majid Sheykhzade; Paul Robert Hansen Journal: Int J Mol Sci Date: 2020-02-17 Impact factor: 5.923
Authors: Robert M Caudle; Stephanie L Caudle; Natalie D Flenor; Eric L Rohrs; John K Neubert Journal: Front Pharmacol Date: 2020-12-03 Impact factor: 5.810